Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Krismer, F.
Expression Profile of Metalloproteases in Neuroendocrine Tumour Cell Lines
Humanmedizin; [ Diplomarbeit ] Medical University of Graz; 2014. pp. 97
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Ghaffari Tabrizi-Wizsy Nassim
- Altmetrics:
- Abstract:
- Neuroendocrine Tumours (NETs) are indolent neoplasms occurring all over the body. Despite their typically slow growth, they are primarily detected when already metastasized. Since NETs are relatively insensitive to radiation therapy as well as chemotherapy, new approaches for novel treatments are urgently needed. Overexpressed Metalloproteases have shown to play a crucial role in the process of tumour progression and metastasis and might therefore be considered valuable therapeutic targets. With a rising incidence every year the relevance of Neuroendocrine Tumours will be considered equal to testicular cancer or myeloma in 2015. Aims: Since Metalloproteases are not well studied in NETs, the aim of this study was to explore expression profiles of the currently known A Disintegrin and Metalloproteases (ADAMs) and Matrix Metalloproteases (MMPs) for 10 Medullary Thyroid Carcinoma (MTC) and 2 Small Intestine NET (SI-NET) cell lines. Methods: The expression analysis was performed at Ribonucleic Acid (RNA) level. Therefore total RNA was isolated from MTC cell lines BOJO, GRS-IV, GRS-V, HEVE-II, MTC-SK, OEE-III, RARE, SHER-1, SINJ, TT and SI-NET cell lines P-STS and KRJ-I, following Reverse Transcription and Polymerase Chain Reaction (RT-PCR). The design of appropriate PCR primers of human MMPs and ADAMs was also a major part of this work. Results and conclusion: We could create expression profiles of the currently known ADAMs and MMPs in 10 MTC and 2 SI-NET cell lines. Summarized our findings report a generally high protease expression for ADAMs, with ADAM 10, 15, 17, 21 and 22 expressed throughout all cell lines. Contrary, MMP expression was rather low, with only MMP 7 present in most NET cell lines. In accordance with the current literature we proclaim closer investigation of ADAM 10, 15 and 17 as putative biomarkers for MTC. However, further investigation is needed to ascertain the utility of Metalloproteases as a target for anti-neoplastic agents, or as prognostic biomarkers for NETs.